--- title: "Plozasiran | PepTracker Pro" url: https://peptrackerpro.com/peptides/plozasiran description: "An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Plozasiran High Evidence An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population. Aliases ARO-APOC3 +3 more Evidence High Evidence Last Updated 2026-08-11 Reading Time 4 min ## What It Is Plozasiran (development code ARO-APOC3, marketed as Redemplo) is a small interfering RNA (siRNA) therapeutic developed by Arrowhead Pharmaceuticals using its proprietary Targeted RNAi Molecule (TRiM) platform with GalNAc conjugation for liver-directed delivery. It silences the messenger RNA that encodes apolipoprotein C-III (apoC-III), a liver-made protein that raises blood triglycerides by inhibiting lipoprotein lipase and slowing the clearance of triglyceride-rich lipoprotein remnants. By reducing apoC-III production, plozasiran allows the body to break down and clear triglycerides more efficiently. It is administered as a subcutaneous injection once every three months (quarterly), a dosing convenience that distinguishes it from daily oral or more frequent injectable lipid drugs. On November 18, 2025 the U.S. FDA approved plozasiran as Redemplo, an adjunct to diet, to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) - a rare, severe genetic disorder in which triglycerides can exceed 1,000 mg/dL and drive recurrent, life-threatening acute pancreatitis. It has also been approved in China (NMPA) and Australia (TGA) for FCS. Arrowhead is now pursuing the much larger indication of severe hypertriglyceridemia (sHTG), where positive Phase 3 SHASTA-3 and SHASTA-4 topline results were reported on July 22, 2026 and a supplemental New Drug Application (sNDA) is planned before the end of 2026. Also known as: ARO-APOC3, Redemplo, apoC-III siRNA, apolipoprotein C-III RNAi ## Regulatory Status Approved (FCS) - investigational for severe hypertriglyceridemia Plozasiran is FDA-approved under the brand name Redemplo (approved November 18, 2025) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), and is also approved for FCS in China (NMPA) and Australia (TGA). For the broader indication of severe hypertriglyceridemia (sHTG) it remains investigational; Arrowhead received FDA Breakthrough Therapy Designation in sHTG and plans to submit a supplemental New Drug Application (sNDA) before the end of 2026 following positive Phase 3 SHASTA-3 and SHASTA-4 results. ## Why Researchers Study It Plozasiran is the drug that turned apoC-III from a lab target into an approved medicine for the hardest triglyceride problem in medicine. Familial chylomicronemia syndrome (FCS) is a rare genetic disorder in which triglycerides run so high - often above 1,000 or even 2,000 mg/dL - that patients suffer repeated bouts of acute pancreatitis, a painful and potentially fatal inflammation of the pancreas, with almost no effective treatment beyond a near-fat-free diet. What makes plozasiran compelling is not just that it lowers triglycerides by roughly 80% with a single injection every three months, but that this translated into a large, meaningful drop in actual pancreatitis events - the outcome that matters to patients. It is also a proof point for RNA interference as a durable, quarterly-dosed way to switch off a liver gene, and its success in the much larger severe hypertriglyceridemia population (millions of people, not the few thousand with FCS) could reshape how common high triglycerides are treated. ## Proposed Mechanisms - Small interfering RNA (siRNA) that silences the messenger RNA encoding apolipoprotein C-III (apoC-III) in the liver, reducing apoC-III production - Uses Arrowhead's TRiM platform with a GalNAc (N-acetylgalactosamine) sugar tag that targets delivery to liver hepatocytes via the asialoglycoprotein receptor - Lowering apoC-III restores lipoprotein lipase activity and speeds hepatic clearance of triglyceride-rich lipoprotein remnants, cutting blood triglycerides - Also reduces non-HDL cholesterol, remnant cholesterol and apoB, and tends to raise HDL cholesterol - Reduces acute pancreatitis risk by removing the extreme chylomicronemia that triggers it - Administered subcutaneously once every three months (quarterly), giving durable triglyceride lowering between doses ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 3 (PALISADE, NEJM 2024) | 75 adults with persistent chylomicronemia (with or without genetically confirmed FCS); plozasiran 25 mg or 50 mg vs placebo subcutaneously every 3 months for 12 months | Median fasting triglycerides fell 80% (25 mg) and 78% (50 mg) vs 17% with placebo at 10 months (placebo-adjusted roughly -57% to -59%); significantly fewer adjudicated acute pancreatitis events vs placebo; met all alpha-controlled endpoints | Source | | Phase 3 (SHASTA-3 and SHASTA-4, topline July 22, 2026) | ~750 adults total with severe hypertriglyceridemia (triglycerides >= 500 mg/dL); plozasiran 25 mg subcutaneously every 3 months vs placebo | Met primary endpoint: median triglyceride reductions of 79% (SHASTA-3) and 81% (SHASTA-4); statistically significant reduction in acute pancreatitis events across the pooled sHTG population (up to ~78-100% event reduction in high-risk subgroups); no new safety signals | Source | | Phase 2b (SHASTA-2 / MUIR, prior) | Adults with severe hypertriglyceridemia and with mixed hyperlipidemia; multiple plozasiran doses vs placebo | Dose-dependent apoC-III and triglyceride lowering that supported the Phase 3 program and dose selection (25 mg quarterly) | Source | ## Commonly Discussed Benefits Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Disease Modification: https://peptrackerpro.com/benefits/disease-modification Researching Plozasiran? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=plozasiran) ## Safety & Cautions - Approved specifically for familial chylomicronemia syndrome (FCS) as Redemplo; use for the broader severe hypertriglyceridemia population is still investigational pending FDA review of a planned supplemental NDA - Long-term cardiovascular outcomes (heart attack and stroke reduction) have not been established; the proven benefits to date are triglyceride lowering and reduced acute pancreatitis events - Modest increases in blood glucose / HbA1c and reports of worsening glycemic control have been seen with apoC-III-targeting therapies and warrant monitoring, particularly in people with diabetes - As an injectable prescription biologic it must be given by or under the supervision of a healthcare provider; it is not a supplement or research chemical, and any 'plozasiran' or 'ARO-APOC3' sold by a vendor is unverified and unsafe - Common adverse effects reported include injection-site reactions and, in some studies, extremity pain or transient liver enzyme changes ## Comparisons See how Plozasiran compares to related peptides: Plozasiran vs Eplontersen: https://peptrackerpro.com/compare/plozasiran-vs-eplontersen Plozasiran vs Inclisiran: https://peptrackerpro.com/compare/plozasiran-vs-inclisiran Plozasiran vs Lepodisiran: https://peptrackerpro.com/compare/plozasiran-vs-lepodisiran Plozasiran vs Muvalaplin: https://peptrackerpro.com/compare/plozasiran-vs-muvalaplin Plozasiran vs Obicetrapib: https://peptrackerpro.com/compare/plozasiran-vs-obicetrapib Plozasiran vs Olezarsen: https://peptrackerpro.com/compare/plozasiran-vs-olezarsen Plozasiran vs Olpasiran: https://peptrackerpro.com/compare/plozasiran-vs-olpasiran Plozasiran vs Pelacarsen: https://peptrackerpro.com/compare/plozasiran-vs-pelacarsen Plozasiran vs Solbinsiran: https://peptrackerpro.com/compare/plozasiran-vs-solbinsiran Plozasiran vs Vutrisiran: https://peptrackerpro.com/compare/plozasiran-vs-vutrisiran Plozasiran vs Zerlasiran: https://peptrackerpro.com/compare/plozasiran-vs-zerlasiran Plozasiran vs Zilebesiran: https://peptrackerpro.com/compare/plozasiran-vs-zilebesiran Plozasiran vs Ziltivekimab: https://peptrackerpro.com/compare/plozasiran-vs-ziltivekimab Plozasiran vs Zodasiran: https://peptrackerpro.com/compare/plozasiran-vs-zodasiran Plozasiran vs ARO-INHBE: https://peptrackerpro.com/compare/plozasiran-vs-aro-inhbe ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Watts GF, et al. - Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk (PALISADE, Phase 3), New England Journal of Medicine (2024/2025) PubMed (https://www.nejm.org/doi/abs/10.1056/NEJMoa2409368) 2. [2] Arrowhead Pharmaceuticals - FDA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (November 18, 2025) PubMed (https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-fda-approval-redemplor) 3. [3] Arrowhead Pharmaceuticals - Topline Phase 3 SHASTA-3 and SHASTA-4 Results in Severe Hypertriglyceridemia (July 22, 2026) PubMed (https://arrowheadpharma.com/en-us/newsroom/arrowhead-pharmaceuticals-reports-topline-results-phase-3-shasta) 4. [4] FDA - Approves drug to reduce triglycerides in adults with familial chylomicronemia syndrome PubMed (https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-reduce-triglycerides-adults-familial-chylomicronemia-syndrome) 5. [5] HCPLive - Plozasiran Meets Primary Endpoint in SHASTA-3, SHASTA-4 sHTG Trials PubMed (https://www.hcplive.com/view/plozasiran-meets-primary-endpoint-in-shasta-3-shasta-4-shtg-trials) ### Keep researching in the app - Log Plozasiran to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=plozasiran Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Eplontersen High Evidence An approved, once-monthly, self-administered subcutaneous GalNAc-conjugated antisense oligonucleotide (ASO) from Ionis and AstraZeneca that treats transthyretin-mediated (ATTR) amyloidosis by lowering the liver's production of transthyretin (TTR). Transthyretin is a liver-made transport protein that can misfold and deposit as amyloid in nerves and the heart; eplontersen is a short synthetic strand of chemically modified DNA/RNA that binds TTR messenger RNA and directs its enzymatic (RNase H1) degradation before the protein is made, cutting circulating TTR by roughly 80%. A triantennary N-acetylgalactosamine (GalNAc) tag delivers it to liver cells, allowing a low-dose 45 mg injection just once a month via autoinjector or pre-filled syringe. Marketed as Wainua (US) and Wainzua (EU), it was FDA-approved in December 2023 for the polyneuropathy of hereditary ATTR amyloidosis (ATTRv-PN) on the strength of the NEURO-TTRansform trial, and is now approved in more than 20 countries. Eplontersen is the antisense (ASO) counterpart to the siRNA drug vutrisiran (Amvuttra): both silence TTR, and both were tested in ATTR cardiomyopathy - but where vutrisiran's HELIOS-B trial succeeded on top of a stabilizer background, eplontersen's much larger CARDIO-TTRansform cardiomyopathy trial missed its primary endpoint in July 2026, with a benefit seen only in the prespecified monotherapy subgroup. It is a GalNAc-ASO sibling of Ionis's olezarsen and pelacarsen and the second-generation successor to the earlier, non-GalNAc TTR antisense drug inotersen (Tegsedi). Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular View Details: https://peptrackerpro.com/peptides/eplontersen \+ Compare: https://peptrackerpro.com/compare?select=eplontersen Track in App: https://app.peptrackerpro.com/?add=eplontersen ### Inclisiran High Evidence An approved, twice-yearly subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Novartis (originally discovered by Alnylam) that lowers LDL cholesterol by silencing PCSK9 (proprotein convertase subtilisin/kexin type 9), the liver protein that destroys LDL receptors. By switching off PCSK9 production inside hepatocytes, inclisiran leaves more LDL receptors on the liver surface to pull LDL cholesterol out of the blood - achieving roughly a 50% LDL reduction with an injection given only twice a year after a loading dose. Marketed as Leqvio, it was the first siRNA medicine approved for a chronic cardiovascular condition: the EU cleared it in December 2020 and the FDA in December 2021, and in July 2025 the FDA expanded the U.S. label to first-line monotherapy, dropping the requirement that it be added on top of a statin. Its Phase 3 ORION-9, ORION-10 and ORION-11 trials established the LDL benefit; a large cardiovascular outcomes program (VICTORION-2-PREVENT and others) is still running to test whether that LDL lowering prevents heart attacks and strokes. Inclisiran is the approved, real-world proof-of-concept for the GalNAc-siRNA cardiometabolic platform that newer investigational agents like zodasiran, solbinsiran, olpasiran and plozasiran build on. View Details: https://peptrackerpro.com/peptides/inclisiran \+ Compare: https://peptrackerpro.com/compare?select=inclisiran Track in App: https://app.peptrackerpro.com/?add=inclisiran ### Lepodisiran Medium Evidence An investigational, long-duration injectable small interfering RNA (siRNA) from Eli Lilly that lowers lipoprotein(a) [Lp(a)] by nearly 94% by silencing the LPA gene in the liver. A single dose keeps Lp(a) suppressed for a year or more, and its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes trial to include people who have not yet had a cardiovascular event. View Details: https://peptrackerpro.com/peptides/lepodisiran \+ Compare: https://peptrackerpro.com/compare?select=lepodisiran Track in App: https://app.peptrackerpro.com/?add=lepodisiran ### Muvalaplin Medium Evidence The first oral, small-molecule inhibitor of lipoprotein(a) [Lp(a)] formation, from Eli Lilly. Instead of silencing a gene, muvalaplin is a once-daily pill that physically blocks apolipoprotein(a) from binding apolipoprotein B — the first step in building an Lp(a) particle. In its Phase 2 KRAKEN trial (published in JAMA, 2024) it cut Lp(a) by up to ~86% (placebo-adjusted) and, as of 2026, is the only Lp(a)-lowering drug that is both oral and already enrolling a large Phase 3 cardiovascular outcomes trial (MOVE-Lp(a)). View Details: https://peptrackerpro.com/peptides/muvalaplin \+ Compare: https://peptrackerpro.com/compare?select=muvalaplin Track in App: https://app.peptrackerpro.com/?add=muvalaplin ### Obicetrapib Medium Evidence An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026. View Details: https://peptrackerpro.com/peptides/obicetrapib \+ Compare: https://peptrackerpro.com/compare?select=obicetrapib Track in App: https://app.peptrackerpro.com/?add=obicetrapib ### Olezarsen High Evidence An FDA-approved subcutaneous antisense oligonucleotide (ASO) from Ionis Pharmaceuticals, branded Tryngolza, that lowers triglycerides by silencing the messenger RNA for apolipoprotein C-III (apoC-III). Self-injected once a month, it was the first-ever therapy approved for familial chylomicronemia syndrome (FCS) on December 19, 2024, and on June 24, 2026 it became the first and only treatment approved to reduce both triglycerides and the risk of acute pancreatitis in the far larger severe hypertriglyceridemia (sHTG) population. View Details: https://peptrackerpro.com/peptides/olezarsen \+ Compare: https://peptrackerpro.com/compare?select=olezarsen Track in App: https://app.peptrackerpro.com/?add=olezarsen ### Olpasiran Medium Evidence An investigational, once-every-12-weeks injectable small interfering RNA (siRNA) from Amgen that lowers lipoprotein(a) [Lp(a)] by up to ~97% by silencing the LPA gene in the liver. Its Phase 3 OCEAN(a)-Outcomes cardiovascular outcomes trial (~7,000 patients) is one of the pivotal readouts — due December 2026 — that will help decide whether lowering Lp(a) prevents heart attacks and strokes. View Details: https://peptrackerpro.com/peptides/olpasiran \+ Compare: https://peptrackerpro.com/compare?select=olpasiran Track in App: https://app.peptrackerpro.com/?add=olpasiran ### Pelacarsen Medium Evidence A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026. View Details: https://peptrackerpro.com/peptides/pelacarsen \+ Compare: https://peptrackerpro.com/compare?select=pelacarsen Track in App: https://app.peptrackerpro.com/?add=pelacarsen ### Solbinsiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program. View Details: https://peptrackerpro.com/peptides/solbinsiran \+ Compare: https://peptrackerpro.com/compare?select=solbinsiran Track in App: https://app.peptrackerpro.com/?add=solbinsiran ### Vutrisiran High Evidence An approved, quarterly (once-every-three-months) subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam that treats transthyretin-mediated (ATTR) amyloidosis by silencing the TTR gene in the liver. Transthyretin is a liver-made transport protein that can misfold and pile up as amyloid deposits in nerves and, critically, the heart; vutrisiran uses RNA interference (RNAi) to degrade both mutant and wild-type TTR messenger RNA before the protein is made, lowering circulating TTR by roughly 80% and starving the amyloid of its raw material. Marketed as Amvuttra, it was first FDA-approved in June 2022 for the polyneuropathy of hereditary ATTR amyloidosis (HELIOS-A), and in March 2025 the FDA expanded the label to ATTR cardiomyopathy (ATTR-CM) of wild-type or hereditary disease - making vutrisiran the first RNAi therapeutic shown to reduce cardiovascular death and cardiovascular events, on the strength of the HELIOS-B outcomes trial. It shares the exact GalNAc-siRNA delivery platform that underlies the cardiometabolic RNAi medicine inclisiran and the investigational agents olpasiran, lepodisiran, zerlasiran, zilebesiran, zodasiran, solbinsiran and plozasiran, and it is the direct successor to Alnylam's earlier intravenous TTR siRNA patisiran (Onpattro). Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/vutrisiran \+ Compare: https://peptrackerpro.com/compare?select=vutrisiran Track in App: https://app.peptrackerpro.com/?add=vutrisiran ### Zerlasiran Medium Evidence An investigational, long-acting injectable small interfering RNA (siRNA) from Silence Therapeutics that lowers lipoprotein(a) [Lp(a)] by more than 80% by silencing the LPA gene in the liver. Dosed only every 16–24 weeks, it produced durable ~90% reductions in its Phase 2 ALPACAR-360 trial (published in JAMA, 2024); as of 2026 the company is seeking a partner before starting its Phase 3 cardiovascular outcomes study. View Details: https://peptrackerpro.com/peptides/zerlasiran \+ Compare: https://peptrackerpro.com/compare?select=zerlasiran Track in App: https://app.peptrackerpro.com/?add=zerlasiran ### Zilebesiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam Pharmaceuticals and Roche/Genentech that lowers blood pressure by silencing angiotensinogen (AGT), the single upstream precursor of the renin-angiotensin-aldosterone system (RAAS). Designed for dosing as infrequently as once or twice a year, it is the first RNА interference (RNAi) therapeutic developed for hypertension. In Phase 2 KARDIA-1 and KARDIA-2 trials it produced durable, clinically meaningful reductions in systolic blood pressure sustained for up to 6 months from a single dose, and in 2025 it advanced into the large Phase 3 ZENITH cardiovascular outcomes trial. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/zilebesiran \+ Compare: https://peptrackerpro.com/compare?select=zilebesiran Track in App: https://app.peptrackerpro.com/?add=zilebesiran ### Ziltivekimab Medium Evidence An investigational, fully human monoclonal antibody that neutralizes the pro-inflammatory cytokine interleukin-6 (IL-6) to test whether lowering vascular inflammation - independently of cholesterol - can prevent heart attacks, strokes and cardiovascular death. Given as a low-volume, once-monthly 15 mg subcutaneous injection (half-life ~57 days), ziltivekimab was originally developed by Corvidia Therapeutics and acquired by Novo Nordisk in 2020 for up to $2.1 billion. It is the flagship clinical test of the 'residual inflammatory risk' hypothesis that grew out of the CANTOS trial of the IL-1 beta antibody canakinumab: the idea that many high-risk patients keep having cardiovascular events because of ongoing inflammation (marked by high-sensitivity C-reactive protein, hsCRP) even when LDL cholesterol is well controlled. In the Phase 2 RESCUE trial ziltivekimab cut hsCRP by up to ~92%, and it advanced into three large Phase 3 cardiovascular outcomes trials - ZEUS, HERMES and ARTEMIS. On July 31, 2026, Novo Nordisk announced that the pivotal ZEUS trial (>6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation) MISSED its primary endpoint: despite clear target engagement (large falls in free IL-6 and hsCRP), ziltivekimab did not reduce major adverse cardiovascular events versus placebo (hazard ratio 0.99, 95% CI 0.88-1.11). The heart-failure trial HERMES and the post-heart-attack trial ARTEMIS continue, with readouts expected in the first half of 2027. Ziltivekimab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. Inflammation: https://peptrackerpro.com/benefits/inflammation Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management View Details: https://peptrackerpro.com/peptides/ziltivekimab \+ Compare: https://peptrackerpro.com/compare?select=ziltivekimab Track in App: https://app.peptrackerpro.com/?add=ziltivekimab ### Zodasiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Arrowhead Pharmaceuticals that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made regulator of fat metabolism. By switching off ANGPTL3 production, zodasiran deeply reduces triglycerides, remnant cholesterol and LDL cholesterol through a pathway that does not depend on the LDL receptor - making it especially relevant for people, such as those with homozygous familial hypercholesterolemia (HoFH), whose LDL receptors barely work. In the Phase 2b ARCHES-2 trial (NEJM 2024) it produced durable, dose-dependent reductions in triglycerides, remnant cholesterol and ANGPTL3, and in the Phase 2 GATEWAY study it lowered LDL cholesterol by about 40% in HoFH. It is now in the Phase 3 YOSEMITE trial in HoFH, which completed enrollment in July 2026. View Details: https://peptrackerpro.com/peptides/zodasiran \+ Compare: https://peptrackerpro.com/compare?select=zodasiran Track in App: https://app.peptrackerpro.com/?add=zodasiran ### ARO-INHBE Low Evidence An investigational RNA-interference (RNAi) therapeutic from Arrowhead Pharmaceuticals designed to treat obesity by silencing a fat-storage gene in the liver. ARO-INHBE is a GalNAc-conjugated small interfering RNA (siRNA) that reduces hepatic expression of the INHBE gene and its secreted product, the hepatokine Activin E. INHBE is a genetically validated target: people who naturally carry rare loss-of-function variants in INHBE have a healthier (less abdominal) fat distribution and a lower risk of type 2 diabetes, suggesting that lowering Activin E with a drug could reproduce that protective metabolic profile. In an ongoing Phase 1/2a trial (AROINHBE-1001, NCT06700538), a single subcutaneous dose reduced serum Activin E by up to about 94%, and monotherapy reduced visceral fat by roughly 10-16% while modestly increasing lean tissue. Most strikingly, when added to the incretin drug tirzepatide in obese patients with type 2 diabetes, ARO-INHBE roughly doubled weight loss (-9.4% versus -4.8% at week 16) and roughly tripled reductions in visceral, total, and liver fat versus tirzepatide alone. These are small, early, interim results (as few as 3-4 participants per combination arm) - not proof of durable or long-term benefit. ARO-INHBE is investigational, is not approved anywhere, and is not a supplement or research chemical; it is studied only in clinical trials. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Weight Management (https://peptrackerpro.com/benefits/weight-management)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/aro-inhbe \+ Compare: https://peptrackerpro.com/compare?select=aro-inhbe Track in App: https://app.peptrackerpro.com/?add=aro-inhbe ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Plozasiran", "description": "An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population.", "url": "https://peptrackerpro.com/peptides/plozasiran", "lastReviewed": "2026-08-11", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Plozasiran", "item": "https://peptrackerpro.com/peptides/plozasiran" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People with familial chylomicronemia syndrome (FCS) or a history of triglyceride-induced acute pancreatitis looking for an approved therapy beyond an extreme low-fat diet?", "acceptedAnswer": { "@type": "Answer", "text": "Plozasiran is a research peptide studied in preclinical models. An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population." } }, { "@type": "Question", "name": "Patients with severe hypertriglyceridemia who have not reached goal on fibrates, fish oil or existing therapy and are watching the FDA review for that indication?", "acceptedAnswer": { "@type": "Answer", "text": "Plozasiran is a research peptide studied in preclinical models. An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population." } }, { "@type": "Question", "name": "Clinicians and researchers comparing plozasiran with the competing apoC-III antisense drug olezarsen (Tryngolza) and with the broader class of RNAi lipid therapies?", "acceptedAnswer": { "@type": "Answer", "text": "Plozasiran is a research peptide studied in preclinical models. An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population." } }, { "@type": "Question", "name": "People interested in RNA interference (siRNA) medicines and quarterly-dosed, liver-targeted GalNAc therapeutics?", "acceptedAnswer": { "@type": "Answer", "text": "Plozasiran is a research peptide studied in preclinical models. An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population." } } ] } ] ```